Epizyme, Inc. (EPZM) Forecasted to Post FY2017 Earnings of ($2.54) Per Share
Epizyme, Inc. (NASDAQ:EPZM) – Research analysts at Oppenheimer Holdings increased their FY2017 EPS estimates for Epizyme in a research note issued to investors on Tuesday. Oppenheimer Holdings analyst L. Cann now forecasts that the biopharmaceutical company will earn ($2.54) per share for the year, up from their previous estimate of ($2.67). Oppenheimer Holdings currently has a “Buy” rating and a $26.00 target price on the stock. Oppenheimer Holdings also issued estimates for Epizyme’s Q4 2017 earnings at ($0.73) EPS, Q1 2018 earnings at ($0.74) EPS, Q2 2018 earnings at ($0.78) EPS, Q3 2018 earnings at ($0.77) EPS, Q4 2018 earnings at ($0.11) EPS, FY2018 earnings at ($2.39) EPS, FY2019 earnings at ($0.19) EPS and FY2021 earnings at $3.46 EPS.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.08. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $3.95 million. During the same period in the previous year, the firm posted ($0.49) earnings per share. The business’s revenue was up 2027.7% compared to the same quarter last year. ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/22/epizyme-inc-epzm-forecasted-to-post-fy2017-earnings-of-2-54-per-share.html.
Several other equities research analysts have also issued reports on the stock. Jefferies Group LLC assumed coverage on shares of Epizyme in a research note on Wednesday. They set a “buy” rating and a $23.00 target price on the stock. Cann restated a “buy” rating and set a $26.00 price target on shares of Epizyme in a research report on Tuesday. Royal Bank Of Canada restated a “buy” rating and set a $20.00 price target on shares of Epizyme in a research report on Friday, September 15th. BidaskClub upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Finally, Leerink Swann restated an “outperform” rating and set a $28.00 price target (down previously from $31.00) on shares of Epizyme in a research report on Wednesday, August 9th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Epizyme currently has an average rating of “Buy” and an average price target of $23.33.
Shares of Epizyme (NASDAQ EPZM) opened at 18.70 on Thursday. The company’s market capitalization is $1.09 billion. The stock has a 50 day moving average price of $15.50 and a 200 day moving average price of $15.25. Epizyme has a one year low of $8.38 and a one year high of $19.60.
In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $13.44, for a total transaction of $201,600.00. Following the completion of the sale, the insider now owns 22,228 shares in the company, valued at approximately $298,744.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew E. Singer sold 3,024 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The stock was sold at an average price of $15.50, for a total transaction of $46,872.00. Following the sale, the chief financial officer now owns 40,529 shares of the company’s stock, valued at approximately $628,199.50. The disclosure for this sale can be found here. Insiders have sold a total of 48,024 shares of company stock valued at $706,722 in the last 90 days. Insiders own 25.20% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc increased its holdings in shares of Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. acquired a new stake in shares of Epizyme during the 1st quarter worth approximately $175,000. BB&T Securities LLC acquired a new stake in shares of Epizyme during the 2nd quarter worth approximately $181,000. Trexquant Investment LP acquired a new stake in shares of Epizyme during the 2nd quarter worth approximately $184,000. Finally, SG Americas Securities LLC increased its holdings in shares of Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 6,072 shares during the last quarter. Institutional investors and hedge funds own 83.74% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.